Blood-brain barrier-penetrant pharmacological strategies for neuroinflammation in Alzheimer’s disease: small molecules and engineered peptides
Recognition of Alzheimer’s disease (AD) as a neuroinflammatory disorder, alongside amyloid-β and tau pathology, necessitates the development of innovative therapies capable of overcoming blood–brain barrier (BBB)-mediated limitations to brain drug delivery. This review discusses current efforts to develop BBB-permeable...